tetano
Editor, Senior Moderator
Immunotherapy
. 2020 Sep 8.
doi: 10.2217/imt-2020-0220. Online ahead of print.
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Jos? Mar?a D?ez[SUP] 1 [/SUP], Carolina Romero[SUP] 1 [/SUP], J?lia Vergara-Alert[SUP] 2 [/SUP], Melissa Bell?-Perez[SUP] 3 [/SUP], Jordi Rodon[SUP] 2 [/SUP], Jos? Manuel Honrubia[SUP] 3 [/SUP], Joaquim Segal?s[SUP] 4 5 [/SUP], Isabel Sola[SUP] 3 [/SUP], Luis Enjuanes[SUP] 3 [/SUP], Rodrigo Gajardo[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Cross-reactivity against human coronaviruses with Flebogamma[SUP]?[/SUP] DIF and Gamunex[SUP]?[/SUP]-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
Keywords: COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; cross-neutralization; intravenous immunoglobulin.
. 2020 Sep 8.
doi: 10.2217/imt-2020-0220. Online ahead of print.
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Jos? Mar?a D?ez[SUP] 1 [/SUP], Carolina Romero[SUP] 1 [/SUP], J?lia Vergara-Alert[SUP] 2 [/SUP], Melissa Bell?-Perez[SUP] 3 [/SUP], Jordi Rodon[SUP] 2 [/SUP], Jos? Manuel Honrubia[SUP] 3 [/SUP], Joaquim Segal?s[SUP] 4 5 [/SUP], Isabel Sola[SUP] 3 [/SUP], Luis Enjuanes[SUP] 3 [/SUP], Rodrigo Gajardo[SUP] 1 [/SUP]
Affiliations
- PMID: 32900263
- DOI: 10.2217/imt-2020-0220
Abstract
Background: Cross-reactivity against human coronaviruses with Flebogamma[SUP]?[/SUP] DIF and Gamunex[SUP]?[/SUP]-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
Keywords: COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; cross-neutralization; intravenous immunoglobulin.